Malaria recombinant poxviruses
US5766597A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Jun 9, 1994 |
| Grant date | Jun 16, 1998 |
| Priority date | — |
| Expiry date | Jun 9, 2014 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
What is described is a recombinant poxvirus, such as vaccinia or canarypox virus, containing foreign DNA from Plasmodium such as coding for at least one of CSP, PfSSP2, LSA-1, LSA-1-repeatless, MSA-1, SERA, AMA-1, Pfs25, MSA-1 N-terminal p83 and MSA-1 C-terminal gp42. What is also described is a vaccine containing the recombinant poxvirus for inducing an immunological response in a host animal inoculated with the vaccine. Preferred recombinants have attenuated virulence. In certain embodiments the vaccinia has deleted or disrupted the thymidine kinase gene, the hemorrhagic region, the A type inclusion body region, the host range gene region and, the large subunit, ribonucleotide reductase; and, contains coding sequences for CSP, PfSSP2, LSA-1-repeatless, MSA-1, SERA, AMA-1 and Pfs25. That embodiment is termed NYVAC-Pf7 and is a multicomponent, multistage vaccine since it codes for and expresses sporozoite proteins, liver stage proteins, blood stage proteins and, sexual stage proteins.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.